One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly

Label Warning Will Be Key

15 Feb 2021

• By Andrew McConaghie

AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.

Blood transfusion — Roxadustat has been developed for patients with chronic kidney disease-induced anemia, regardless of whether they dependent on blood transfusions or not.

More from Business

More from Scrip